




ResonanceHealth

Building towards success



AGM Presentation

14th November, 2005

Business focus

Resonance Health is developing and commercialising novel applications of Magnetic Resonance Imaging (MRI) to assist with the diagnosis and management of human diseases.

FerriScan: World leading non-invasive test for measurement of liver iron levels has secured regulatory approvals and has been launched commercially.

Our second product for measuring liver fibrosis is in late proof of concept stage and will enter clinical development in 2006.

A growing market – Speciality Diagnostics

Specialty Diagnostics are becoming increasingly important as new clinical algorithms and therapies are developed.

Old

Diagnosis

>\$20 billion; 6-7% growth

Outcome

New

Susceptibility

Diagnosis

Treatment
selection

Treatment
monitoring

>\$1 billion; 15% growth


Therapy

Fast growing
High margin
Low regulatory barriers

Building towards success ResonanceHealth



A unique business model



Applies to both FerriScan and new Fibrosis test

Meeting the needs of stakeholders

- *Clinicians want more effective and lower medical (and legal) risk diagnostic techniques*
- *Patients want and expect higher and higher levels of service/care*
- *MRI chains want increase ROI on equipment and greater market share*
- *OEM's want increased equipment sales/servicing and value add product to increase margins*
- *Pharma (and regulators) want better tools to monitor drug development and performance*


A clinical need – Iron Overload

Need to identify presence and degree of iron loading to optimise therapy

Need to monitor efficacy of therapies

	USA
Population	280 M
Haemochromatotics ¹	1.2 M
Clinically significant iron overload ²	<u>760,000</u>

1. Based on published incidence rate of 1:227
2. 1/3 of those people having persistently elevated blood iron markers (including haemochromatotics and others)



A clinical need – Fibrosis

- *Fibrosis of the liver is a massive global medical problem*
- *For all causes there is a need to determine degree of fibrosis to optimise therapy*
- *Biopsy remains “best practice” to confirm development and progression of fibrosis*
- *Hepatitis C:*
 - *~175 million people globally chronically infected by hepatitis C virus*
 - *EU: 5 million , US: 4 million, Japan: 2 million*
- *Non-alcoholic fatty liver disease:*
 - *12 million in the US at risk*

Commercial progress - FerriScan

- *Regulatory clearances*
 - *US, EU and Australia*
- *Channel partners*
 - *DCA, Medtel, US sites*
- *Commercial customers*
 - *Novartis, Thalassemia Clinical Research Network*
- *Reimbursement*
 - *WA State Government*
- *Opinion leader support*
 - *Medical Advisory Board, TCRN*
- *More than 30 MRI sites around the world are already supplying FerriScan*

Commercial progress - FerriScan

'The FerriScan was quick and painless and is an excellent alternative to liver biopsy for patients who want to find out their exact level of iron loading.'

The Haemochromatosis Society is working with the providers of FerriScan, Resonance Health to promote awareness of iron overload and improve health outcomes for people affected by this disease.'

- Margaret Rankin, Haemochromatosis Society of Australia

Development plan - Fibrosis

- *Proof of Concept will be finalised in January*
 - *Patent application filed*
- *Clinical development phase will occur through 2006*
 - *Leading global liver specialists will be involved*
 - *Clinical trials to optimise application and generate data to support regulatory submissions*
- *Established track record of rapid regulatory approvals for products of this type*
 - *US marketing clearance for FerriScan took 6 weeks from submission*
- *Marketing channels being established for FerriScan will be immediately applicable to Fibrosis test => Rapid uptake*

The year ahead

- *Convert foundations to revenue growth*
- *FerriScan expansion*
 - *November / December will see major US push at key specialist meetings*
- *Reimbursement activities*
 - *Duplication of WA agreement in other states,*
 - *Unique coding application in the US*
- *New partnerships*
 - *Radiology, Pharma, OEMs*
- *Fibrosis clinical phase*

Capital Position

- *With increasing revenues, and completion of the corporate restructure, Resonance has sufficient capital to meet current operational needs*
- *Fibrosis program development will be leveraged with further grant support and strategic partnerships*
- *Resonance Health has (at end October) \$2.4 million cash on hand*
 - *\$1 million placement completed, including new institutional and sophisticated investors*
 - *\$790,000 raised through Share Purchase Plan*
- *Up to \$7 million available through exercise of Jan 2007 options*

Summary

Resonance Health is now strongly positioned for successful global commercialisation through to 2007 with further market penetration and significant revenue expected from widespread uptake of FerriScan technology and a pipeline of products under development.

Contacts

Dr James Williams
Managing Director

Email: jamesw@ferriscan.com

Ph: +61 8 9286 5300

Mr Glenn Smith
Marketing Director

Email: glenns@ferriscan.com

Ph: +61 8 9286 5300



Forward looking statements and risks

This presentation contains forward-looking statements that are based on management's current expectations. These statements may differ materially from actual future events or results due to the range of risks and uncertainties associated with the healthcare technology product development process including manufacturing and licensing, risks inherent in the regulatory approval process applicable in the U.S. and Australia including potential delays in obtaining approvals, market acceptance of products, future financial requirements, general economic conditions, and other risks and uncertainties. There can also be no assurance that competitors will not independently develop similar products or processes that seek to circumvent patents owned or licensed by Resonance Health, or that patents owned or licensed by Resonance Health will provide adequate protection or competitive advantage.

Thank You